Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RNTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.06M
- EPS (TTM)
- -$1.51
- Dividend yield
- None
- 52-week range
- 0.284 – 2.10
- Day range
- 0.3352 – 0.3899
- Volume / Avg
- 668.57K / 586.68K
- Beta
- —
- Shares outstanding
- 86.27M
52-week range
RNTX stock today
Rein Therapeutics (RNTX) closed at $0.3369 on Nov 20, down 8.38% (-$0.0308), versus the S&P 500's 3.70% decline. At this level, RNTX sits near the bottom of its 52-week range of $0.284 to $2.10: 84.0% below the high, set on Apr 22, 2026 and 18.6% above the low. RNTX is down 71.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.2%.
Rein Therapeutics has posted a net loss over the last twelve months (EPS of -$1.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Rein Therapeutics
Company profileRein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. James Brian Windsor Ph.D.
- Headquarters
- Austin, TX
- Employees
- 10
- IPO year
- 2017
- Website
- reintx.com
Financial highlights
Full financialsIn fiscal 2025, Rein Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Rein Therapeutics reported a net loss of $49.9 million, compared with a loss of $62.9 million a year earlier. Diluted earnings per share came in at -$1.96.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-49.87M | $-62.88M | $-15.73M | $-27.33M | $-26.16M |
| EPS (diluted) | $-1.96 | $-3.51 | $-3.42 | $-6.02 | $-5.89 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$6.00+1680.94%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.06 vs $-0.10
- Surprise
- +40.00%
RNTX news
All RNTX news- Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data and Reports Third Quarter 2026 Financial ResultsNasdaq
- Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
Rein Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs RNTX |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs RNTX |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs RNTX |
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs RNTX |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs RNTX |
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs RNTX |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs RNTX |
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs RNTX |
Indexes, lists and sector
Rein Therapeutics stock FAQ
What is Rein Therapeutics's stock price today?
RNTX last traded at $0.3369 as of Nov 20, 4:00 PM EST, down 8.38% on the day. Prices are delayed at least 15 minutes.
Does Rein Therapeutics pay a dividend?
No. Rein Therapeutics does not currently pay a regular cash dividend.
Who is Rein Therapeutics's CEO?
Dr. James Brian Windsor Ph.D. is the chief executive officer of Rein Therapeutics Inc., which has about 10 employees.
Has RNTX ever split its stock?
Yes. The most recent RNTX stock split was a 1-for-20 split on Nov 11, 2022.
What is the RNTX 52-week high?
The 52-week high for RNTX is $2.10 and the 52-week low is $0.284. The stock is currently 84.0% below its high.